Predictive oncology stock.

Insiders trading at Predictive Oncology. Over the last 4 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle, and Charles Lee Sr Nuzum.On average, Predictive …According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023. EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares.Predictive Oncology Inc. (POAI) is a science-driven company that leverages its AI and machine learning capabilities to accelerate oncologic drug discovery and enable drug development. The stock price, news, quote and history of POAI are shown on Yahoo …

Predictive Oncology Inc. analyst ratings, historical stock prices, earnings estimates & actuals. POAI updated stock price target summary.Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. Stock Name. Country.Apr 24, 2023 · Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023. EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre ...

Oncology Pharma's stock was trading at $0.3386 at the beginning of the year. Since then, ONPH shares have decreased by 99.9% and is now trading at $0.0002. View the best growth stocks for 2023 here.

Race Oncology Ltd () Stock Market info Recommendations: Buy or sell Race Oncology stock? Sydney Stock Market & Finance report, prediction for the future: You'll find the Race Oncology share forecasts, stock quote and buy / sell signals below.According to present data Race Oncology's RAC shares and potentially its market environment have …Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average of $3.98. Predictive Oncology GAAP EPS of -$0.78, revenue of …4 analysts have issued 12 month price targets for Ikena Oncology's stock. Their IKNA share price targets range from $11.00 to $13.00. On average, they expect the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 677.8% from the stock's current price.POAI 2HR test Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, Skyline, Soluble, and test Predictive Oncology, Inc. engages in …Predictive Oncology Inc. analyst ratings, historical stock prices, earnings estimates & actuals. POAI updated stock price target summary.

According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...

Insiders trading at Predictive Oncology. Over the last 4 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle, and Charles Lee Sr Nuzum.On average, Predictive …

Here are just a few of the top artificial intelligence (AI) stocks to buy and hold today.Predictive Oncology (): The company could be a game-changer in cancer drug development. C3.ai (): After a ...According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...Predictive Oncology “is a data and AI-driven discovery services company that provides predictive models of tumor drug response.” One of Predictive Oncology’s subsidiaries, TumorGenesis ...Nov 14, 2023 · Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023, compared to $455,827 for the comparable period in 2022. The increase in revenues related primarily to higher sales of ... Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023, compared to $455,827 for the comparable period in 2022. The increase in revenues related primarily to higher sales of ...Latest company newsPredictive Oncology forms a strategic partnership that has the potential to revolutionize the field of radiation oncology. Digital newsroomLinks to …Predictions about the future lives of humanity are everywhere, from movies to news to novels. Some of them prove remarkably insightful, while others, less so. Luckily, historical records allow the people of the present to peer into the past...

Predictive Oncology Inc. EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused ...0.73%. $39.94B. Astellas Pharma Inc. -4.37%. ¥3.42T. PYXS | Complete Pyxis Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and ...8 Wall Street research analysts have issued 1-year target prices for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $27.31 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price.What's Happening with POAI Stock Today. Predictive Oncology Inc (POAI) stock has risen 1.56% while the S&P 500 has fallen -0.05% as of 10:07 AM on Thursday, Jun 22. POAI has risen $0.06 from the previous closing price of $3.83 on volume of 25,176 shares. Over the past year the S&P 500 is higher by 16.05% while POAI has fallen -50.82%.Nov 30, 2023 · Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the ... The Predictive Oncology stock forecast is 4.3910063584427 USD for 2024 November 25, Monday; and 14.588 USD for 2028 November 25, Saturday with technical analysis. Predictive Oncology (POAI) stock price prediction is 4.3910063584427 USD.

Predictive Oncology Inc (POAI) stock is trading at $0.29 as of 3:29 PM on Tuesday, Apr 4, a loss of -$0.02, or -5.88% from the previous closing price of $0.31. The stock has traded between $0.28 and $0.31 so far today. Volume today is 336,440 compared to average volume of 417,533.Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to …

Predictive Oncology Inc. 91 43rd Street. Suite 110. Pittsburgh, Pennsylvania 15201. Phone 1 412 432-15000. Industry Medical Equipment/Supplies. Sector Health Care/Life Sciences. Overview Press Releases Events & Presentations Financials & Filings Stock Quote & Chart Corporate Governance Contact Us Stock Quote (POAI) NASDAQ CM: POAI $3.17 Oct 2, 2023 4:00 PM EDT Change 0 (0.00%) Volume 0 Today's Open -- Previous Close $3.17 Today's High $3.20 Today's Low $3.07 52 Week High $13.88 52 Week Low $2.47 Stock Chart The estimated Net Worth of Robert L Myers is at least $346 Thousand dollars as of 25 September 2023. Mr Myers owns over 1,667 units of Predictive Oncology stock worth over $18,305 and over the last 7 years he sold POAI stock worth over $0. In addition, he makes $327,838 as CFO & Sec. at Predictive Oncology.IDXX Vs POAI: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. Start now and save 50% for the first 3 months. Ticker. Company. Your search produced no matches. We currently support US stocks and STOXX Europe 600 stocks.Nov 8, 2023 · PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study ... Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022The upgrade of Predictive Oncology Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...

Third, all of these shares are below a certain price of $ 3. As a result, they are relatively inexpensive, although the definition of penny stocks has changed over time. It basically includes all stocks traded for less than $ 5, although there are no hard and fast rules to talk about. They are here: ObsEva (NASDAQ: OBSV) Predictive oncology ...

The estimated Net Worth of Carl I. Schwartz is at least 4.75 百万$ dollars as of 22 October 2020. Dr Schwartz owns over 640 units of Predictive Oncology stock worth over 4,318,394$ and over the last 7 years he sold POAI stock worth over 544$. In addition, he makes 433,000$ as CEO & Director at Predictive Oncology.

David Johnson biography. David O. Johnson is Senior Vice President - Operations of Skyline Medical Inc. He was previously the Acting Chief Operating Officer for the Company since December 2011 and had been a consultant to medical device companies since October 2010.Dec 1, 2023 · Predictive Oncology Inc. (NASDAQ:POAI) issued its quarterly earnings results on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.60) by $0.60. The medical instruments supplier had revenue of $0.35 million for the quarter, compared to the ... The estimated Net Worth of Daniel E Handley is at least $351 Thousand dollars as of 15 December 2022. Daniel Handley owns over 6,000 units of Predictive Oncology stock worth over $350,584 and over the last 3 years he sold POAI stock worth over $0. In addition, he makes $0 as Director at Predictive Oncology.Quotes Summary Real-Time After-Hours Pre-Market Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is …The estimated Net Worth of J Melville Engle is at least $117 millier dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $113,900 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to …He oversees Predictive Oncology’s solubility and stability contracts for numerous pharmaceutical/biotech companies. From 1981 to 2016, Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X ... The average Predictive Oncology stock forecast 2023 represents a 0.36% increase from the last price of $3.08999991416931. For Predictive Oncology stock forecast for 2024, 12 predictions are offered for each month of 2024 with average Predictive Oncology stock forecast of $3.76, a high forecast of $5.03, and a low …Nov 24, 2023Fiscal Q3 2023 ended 9/30/23. Reported on 11/14/23. Get the latest Predictive Oncology Inc (POAI) real-time quote, historical performance, charts, and other financial information …Predictive Oncolog y : Offers a compelling use case for AI in the area of cancer research. Remark ( MARK ): One of the smallest of small-cap stocks may have one of the biggest upsides of any AI stock.Minitab Statistical Software is a powerful tool that enables businesses to analyze data, identify trends, and make informed decisions. With its advanced capabilities, Minitab can also be used for predictive modeling.

The estimated Net Worth of Robert L Myers is at least $346 Thousand dollars as of 25 September 2023. Mr Myers owns over 1,667 units of Predictive Oncology stock worth over $18,305 and over the last 7 years he sold POAI stock worth over $0. In addition, he makes $327,838 as CFO & Sec. at Predictive Oncology.8 Wall Street research analysts have issued 1-year target prices for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $27.31 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price.Nov 13, 2023 · POAI U.S.: Nasdaq Predictive Oncology Inc. Watch list NEW Set a price target alert Premarket Last Updated: Oct 27, 2023 7:12 a.m. EDT Delayed quote $ 2.8800 0.02 0.70% Before Hours Volume: 35... Instagram:https://instagram. morningstar stocks2009 penny with man on backtop mortgage lenders in ohionyse mfc Mar 22, 2023 · Effective March 16, 2023, Predictive Oncology and Cancer Research Horizons, the world’s largest private funder of cancer research, have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL platform that pairs artificial intelligence (AI) with the world’s largest biobank of tumor samples; Nov 8, 2023 · Leading-edge solution. Predictive Oncology has launched a breakthrough solution at a pivotal time in drug discovery that enables pharmaceutical and biotech companies to expedite drug development and speed time to market. The company’s novel platform technology valued at $400M+ has the power to impact a billion-dollar biopharmaceutical ... nasdaq biotech indexdall e 3 ai Track Predictive Oncology Inc (POAI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors vanguard best funds for retirement According to the issued ratings of 5 analysts in the last year, the consensus rating for Pyxis Oncology stock is Buy based on the current 5 buy ratings for PYXS. The average twelve-month price prediction for Pyxis Oncology is $8.33 with a high price target of $14.00 and a low price target of $4.00. Learn more on PYXS's analyst rating history.Predictive Oncology Inc stock performance at a glance. Check Predictive Oncology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Welcome to Predictive Oncology The leading edge of a new frontier in drug discovery Integrating scientific rigor with machine learning • Overcoming challenges of clinical trials • Improving the probability of success • Collaborating with partners in biopharma • Advancing molecules to medicine with confidence and accuracy Connect with us Changing the game in drug … Home Read More »